ADMA Biologics (Nasdaq: ADMA) printed $124.4 million of Q2 2026 total revenue on August 5, 2026, a 2% headline lift on the year that masks a sharp inside-the-franchise rotation: ASCENIV, the company's flagship later-line primary immune-deficiency (PI) therapy, grew 24% to $102.9 million, while BIVIGAM, the older, price-pressured IVIG product, fell 49% to $19.4 million. The market is paying for that rotation in real time, which is the load-bearing observation of the quarter, because ASCENIV's growth drove gross margin to 69% (versus 55% in Q2 2025) and Adjusted EBITDA to $61.8 million, up 22% year-over-year, even as the legacy BIVIGAM line continued to roll over. Management reiterated full-year 2026 revenue guidance of $530-$560 million and Adjusted EBITDA of $265-$300 million on the same print, while a $500 million buyback authorization has already absorbed $156.4 million of repurchases in the first half of 2026, shrinking the share count from 237.87 million at year-end 2025 to 225.36 million as of June 30, 2026.
We see ADMA as a profitable specialty plasma company whose equity is being mispriced for two reasons that are not symmetric, and the Q2 print forces the resolution. First, the operating story is intact: ASCENIV's June sequential month-over-month utilization growth was the strongest since the first half of 2024, and management has now submitted a 127-patient real-world outcomes study to the November 2026 American College of Allergy, Asthma & Immunology (ACAAI) meeting, the kind of payer-friendly evidence that supports the insulation thesis on the later-line PI market. Second, a putative federal securities class action (Mazzarino v. ADMA Biologics, filed July 10, 2026 in the District of New Jersey, alleging channel-stuffing and a related-party distributor) has cast a shadow on the stock since the late-May 2026 short-seller reports, dragging shares from a 52-week high of $20.46 to $9.91 as of August 11, 2026, a 52% drawdown that left the equity trading at 14.1x trailing earnings and 11.1x forward earnings against 22% trailing Adjusted EBITDA growth. We read the drawdown as the market re-pricing litigation tail risk rather than re-rating the franchise; the falsification clock is the next quarter, when Q3 results are expected to show ASCENIV sequential acceleration to support the reiterated guidance and the buyback cadence that the bull case depends on.
The single load-bearing risk is the securities class action itself, which sits alongside multiple parallel class-action investigations and a 7/10/2026 lead-plaintiff deadline that has already passed. The lawsuit is at a preliminary stage, the company has not accrued a loss, and management has stated the claims are without merit, but the disclosure puts a 25% discount on the stock that we view as overshooting the realistic worst-case outcome, which is most likely a settlement in the $5-20 million range rather than a multi-year punitive damages scenario. The next data point that tests this thesis is the Q3 2026 print, due in early November 2026, where ASCENIV is expected to show the same acceleration pattern that the Q2 print established; if Q3 sequential ASCENIV growth decelerates or if the full-year guidance is reset lower, the buyback and the litigation discount compound into a more durable re-rating to the downside.